Garry A. Neil
InvestorChief Executive Officer at Avalo Therapeutics
About
CEO of Avalo since February 2022 with extensive experience in pharmaceutical R&D and corporate leadership. Previously served as Chief Scientific Officer at Aevi Genomic Medicine and held senior roles at Johnson & Johnson, including Corporate VP of Science & Technology, as well as positions at Merck KGaA, AstraZeneca, and leading academic research institutions.
Colleagues at Avalo Therapeutics
Aaron Kantoff
Board Member at Avalo Therapeutics
Ashley Ivanowicz
Senior Vice President, Human Resources at Avalo Therapeutics
Chris Sullivan
Chief Financial Officer at Avalo Therapeutics
Colleen Matkowski
Senior Vice President, Global Regulatory Affairs and Quality Assurance at Avalo Therapeutics
Dino C. Miano
Senior Vice President, CMC and Technical Operations at Avalo Therapeutics
Gilla Kaplan
Board Member at Avalo Therapeutics
Jennifer Riley
Chief Strategy Officer at Avalo Therapeutics
Kathleen Cohen
Senior Vice President, Clinical Development Operations at Avalo Therapeutics